Thalidomide- and lenalidomide-associated thromboembolism

Cara Angelotta; Charles L. Bennett

doi:10.1016/s1548-5315(11)70074-2

Thalidomide- and lenalidomide-associated thromboembolism

Cara Angelotta^*, Charles L. Bennett

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

With no clinical trials in the offing that could help determine the best way to prevent thromboembolism, and no requirement for drug suppliers to more vigorously inform patients, it's up to clinicians to warn those under their care that VTE is a potentially life-threatening complication of thalidomide and lenalidomide treatment.

Original language	English (US)
Pages (from-to)	147-148
Number of pages	2
Journal	Community Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1016/s1548-5315(11)70074-2
State	Published - Mar 2007

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/s1548-5315(11)70074-2

Cite this

@article{75f7c8d01af5425c84d65535d0a3f736,

title = "Thalidomide- and lenalidomide-associated thromboembolism",

abstract = "With no clinical trials in the offing that could help determine the best way to prevent thromboembolism, and no requirement for drug suppliers to more vigorously inform patients, it's up to clinicians to warn those under their care that VTE is a potentially life-threatening complication of thalidomide and lenalidomide treatment.",

author = "Cara Angelotta and Bennett, {Charles L.}",

year = "2007",

month = mar,

doi = "10.1016/s1548-5315(11)70074-2",

language = "English (US)",

volume = "4",

pages = "147--148",

journal = "Community Oncology",

issn = "1548-5315",

publisher = "BioLink Communications",

number = "3",

}

TY - JOUR

T1 - Thalidomide- and lenalidomide-associated thromboembolism

AU - Angelotta, Cara

AU - Bennett, Charles L.

PY - 2007/3

Y1 - 2007/3

N2 - With no clinical trials in the offing that could help determine the best way to prevent thromboembolism, and no requirement for drug suppliers to more vigorously inform patients, it's up to clinicians to warn those under their care that VTE is a potentially life-threatening complication of thalidomide and lenalidomide treatment.

AB - With no clinical trials in the offing that could help determine the best way to prevent thromboembolism, and no requirement for drug suppliers to more vigorously inform patients, it's up to clinicians to warn those under their care that VTE is a potentially life-threatening complication of thalidomide and lenalidomide treatment.

UR - http://www.scopus.com/inward/record.url?scp=34147105989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147105989&partnerID=8YFLogxK

U2 - 10.1016/s1548-5315(11)70074-2

DO - 10.1016/s1548-5315(11)70074-2

M3 - Article

AN - SCOPUS:34147105989

SN - 1548-5315

VL - 4

SP - 147

EP - 148

JO - Community Oncology

JF - Community Oncology

IS - 3

ER -

Thalidomide- and lenalidomide-associated thromboembolism

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this